Malta - English - Medicines Authority

fresenius kabi limited cestrian court, eastgate way, manor park, runcorn, cheshire wa7 1nt, united kingdom - octreotide - solution for injection - octreotide 500 µg/ml - pituitary and hypothalamic hormones and analogues

United States - English - NLM (National Library of Medicine)

usv north america inc. - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - acromegaly octreotide acetate injection is indicated to reduce blood levels of growth hormone and igf-i (somatomedin c) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. the goal is to achieve normalization of growth hormone and igf-i (somatomedin c) levels (see dosage and administration ). in patients with acromegaly, octreotide acetate injection reduces growth hormone to within normal ranges in 50% of patients and reduces igf-i (somatomedin c) to within normal ranges in 50% to 60% of patients. since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate injection to reduce blood levels of growth hormone and igf-i (somatomedin c) offers potential benefit before the effects of irradiation are manifested. improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not s

United States - English - NLM (National Library of Medicine)

usv north america inc. - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - acromegaly octreotide acetate injection is indicated to reduce blood levels of growth hormone and igf-i (somatomedin c) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. the goal is to achieve normalization of growth hormone and igf-i (somatomedin c) levels (see dosage and administration). in patients with acromegaly, octreotide acetate injection reduces growth hormone to within normal ranges in 50% of patients and reduces igf-i (somatomedin c) to within normal ranges in 50% to 60% of patients. since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate injection to reduce blood levels of growth hormone and igf-i (somatomedin c) offers potential benefit before the effects of irradiation are manifested. improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - octreotide -

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - octreotide acetate - solution for injection - 0.1 mg/ml - somatostatin and analogues

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - octreotide acetate - solution for injection - 50microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - octreotide acetate - solution for injection - 100microgram/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - octreotide acetate - solution for injection - 100 microgram(s)/millilitre - somatostatin and analogues; octreotide

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - octreotide acetate - solution for injection - 200 microgram(s)/millilitre - somatostatin and analogues; octreotide

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - octreotide acetate - solution for injection - 50 microgram(s)/millilitre - somatostatin and analogues; octreotide